1.Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
Seo Yeon YOO ; Eunju KIM ; Gi-Byoung NAM ; Danbi LEE ; Ju Hyun SHIM ; Kang Mo KIM ; Young-Suk LIM ; Han Chu LEE ; Young-Hwa CHUNG ; Yung Sang LEE ; Jonggi CHOI
The Korean Journal of Internal Medicine 2022;37(3):555-566
Background/Aims:
The safety of direct oral anticoagulants (DOACs) compared with warfarin in patients with both nonvalvular atrial fibrillation (AF) and clinically confirmed liver cirrhosis (LC) has not been well studied. We compared the risk of a major bleeding event between DOAC and warfarin treatments in this patient population.
Methods:
A total of 238 cirrhotic patients with AF were retrospectively analyzed. The major bleeding event risk was compared between DOAC- and warfarin-treated groups. The median follow-up duration was 5.6 years.
Results:
Among the 238 study patients with LC and AF, 128 (53.8%) received DOACs and 110 (46.2%) received warfarin. The mean patient age was 68.8 years, and 78.2% were men. A major bleeding event occurred in 10 and 20 patients in the DOAC and warfarin groups, respectively, most commonly caused by gastrointestinal bleeding (70.0%). The cumulative risk of major bleeding did not differ between the groups by log-rank test (p = 0.12). This finding did not change when using 60 propensity score-matched pairs. A multivariable Cox regression model indicated that the concomitant use of antiplatelet agents (adjusted hazard ratio [aHR], 2.06; 95% confidence interval [CI], 1.00 to 4.30; p = 0.048) and presence of esophageal or gastric varices confirmed by endoscopic examination (aHR, 2.31; 95% CI, 1.03 to 5.17; p = 0.04) were associated with major bleeding in the entire cohort.
Conclusions
A major bleeding event risk is not increased by DOAC compared with warfarin treatment. Antiplatelet agent use and varices are independently associated with a higher risk of major bleeding during anticoagulation.
2.Principal Clinical Factors Predicting Therapeutic Outcomes After Surgical Drainage of Postoperative Cheek Cysts: Experience From a Single Center
Sung Woo CHO ; Hyun Jung LIM ; Yoonjae SONG ; Young KANG ; Jae Hyun LIM ; Yung Jin JEON ; Doo Hee HAN ; Tae Bin WON ; Dong Young KIM ; Hyun Jik KIM
Clinical and Experimental Otorhinolaryngology 2019;12(1):79-85
OBJECTIVES: Postoperative cheek cyst (POCC) is a late postoperative complication of radical maxillary sinus surgery including the Caldwell-Luc (C-L) operation. The present study aimed to evaluate the therapeutic outcomes of surgical treatment for POCC and to assess the clinical factors correlated to these outcomes. METHODS: This study included 57 patients (67 nostrils) diagnosed with POCC who underwent surgical drainage. The medical records of the patients were retrospectively reviewed for radiological findings, treatment modalities, residual symptoms, and recurrences. RESULTS: In total, 30 patients were male and 27 patients were female with a mean age of 55 years, and the patients were usually diagnosed with POCC 28.2 years after radical surgery. Endonasal endoscopic marsupialization was performed via inferior meatal antrostomy, and if possible, middle meatal antrostomy was performed at the same time. In patients with cysts that were difficult to reach using an endonasal endoscopic approach, additional open C-L approaches were performed. The median follow-up period was 19.4 months. Overall, adequate drainage and symptomatic relief were achieved in 91% (61/67) of the patients. The recurrence rate was significantly higher in patients who had anterolateral POCC. Failure to achieve symptomatic relief was correlated to a smaller cyst and the use of the open C-L approach for drainage. CONCLUSION: The location and size of the cyst as well as the use of the open surgical approach were important factors in predicting the therapeutic outcome of POCC. The time point of treatment and surgical approaches should be based on the above-mentioned findings.
Cheek
;
Drainage
;
Female
;
Follow-Up Studies
;
Humans
;
Male
;
Maxillary Sinus
;
Medical Records
;
Mucocele
;
Postoperative Complications
;
Recurrence
;
Retrospective Studies
;
Treatment Outcome
3.Analysis of Complications of Percutaneous Transthoracic Needle Biopsy Using CT-Guidance Modalities In a Multicenter Cohort of 10568 Biopsies
Soon Ho YOON ; Chang Min PARK ; Kyung Hee LEE ; Kun Young LIM ; Young Joo SUH ; Dong Jin IM ; Jin HUR ; Dae Hee HAN ; Mi Jin KANG ; Ji Yung CHOO ; Cherry KIM ; Jung Im KIM ; Hyunsook HONG
Korean Journal of Radiology 2019;20(2):323-331
OBJECTIVE: To analyze the complications of percutaneous transthoracic needle biopsy using CT-based imaging modalities for needle guidance in comparison with fluoroscopy in a large retrospective cohort. MATERIALS AND METHODS: This study was approved by multiple Institutional Review Boards and the requirement for informed consent was waived. We retrospectively included 10568 biopsies from eight referral hospitals from 2010 through 2014. In univariate and multivariate logistic analyses, 3 CT-based guidance modalities (CT, CT fluoroscopy, and cone-beam CT) were compared with fluoroscopy in terms of the risk of pneumothorax, pneumothorax requiring chest tube insertion, and hemoptysis, with adjustment for other risk factors. RESULTS: Pneumothorax occurred in 2298 of the 10568 biopsies (21.7%). Tube insertion was required after 316 biopsies (3.0%), and hemoptysis occurred in 550 cases (5.2%). In the multivariate analysis, pneumothorax was more frequently detected with CT {odds ratio (OR), 2.752 (95% confidence interval [CI], 2.325–3.258), p < 0.001}, CT fluoroscopy (OR, 1.440 [95% CI, 1.176–1.762], p < 0.001), and cone-beam CT (OR, 2.906 [95% CI, 2.235–3.779], p < 0.001), but no significant relationship was found for pneumothorax requiring chest tube insertion (p = 0.497, p = 0.222, and p = 0.216, respectively). The incidence of hemoptysis was significantly lower under CT (OR, 0.348 [95% CI, 0.247–0.491], p < 0.001), CT fluoroscopy (OR, 0.594 [95% CI, 0.419–0.843], p = 0.004), and cone-beam CT (OR, 0.479 [95% CI, 0.317–0.724], p < 0.001) guidance. CONCLUSION: Hemoptysis occurred less frequently with CT-based guidance modalities in comparison with fluoroscopy. Although pneumothorax requiring chest tube insertion showed a similar incidence, pneumothorax was more frequently detected using CT-based guidance modalities.
Biopsy
;
Biopsy, Needle
;
Chest Tubes
;
Cohort Studies
;
Cone-Beam Computed Tomography
;
Ethics Committees, Research
;
Fluoroscopy
;
Hemoptysis
;
Image-Guided Biopsy
;
Incidence
;
Informed Consent
;
Lung Neoplasms
;
Multivariate Analysis
;
Needles
;
Pneumothorax
;
Referral and Consultation
;
Retrospective Studies
;
Risk Factors
4.Erratum: Analysis of Complications of Percutaneous Transthoracic Needle Biopsy Using CT-Guidance Modalities In a Multicenter Cohort of 10568 Biopsies
Soon Ho YOON ; Chang Min PARK ; Kyung Hee LEE ; Kun Young LIM ; Young Joo SUH ; Dong Jin IM ; Jin HUR ; Dae Hee HAN ; Mi Jin KANG ; Ji Yung CHOO ; Cherry KIM ; Jung Im KIM ; Hyunsook HONG
Korean Journal of Radiology 2019;20(3):531-531
On page 323, the grant number was incorrectly numbered as HI15C1234. The correct number is HI15C3390.
5.Diagnostic Accuracy of Percutaneous Transthoracic Needle Lung Biopsies: A Multicenter Study
Kyung Hee LEE ; Kun Young LIM ; Young Joo SUH ; Jin HUR ; Dae Hee HAN ; Mi Jin KANG ; Ji Yung CHOO ; Cherry KIM ; Jung Im KIM ; Soon Ho YOON ; Woojoo LEE ; Chang Min PARK
Korean Journal of Radiology 2019;20(8):1300-1310
OBJECTIVE: To measure the diagnostic accuracy of percutaneous transthoracic needle lung biopsies (PTNBs) on the basis of the intention-to-diagnose principle and identify risk factors for diagnostic failure of PTNBs in a multi-institutional setting. MATERIALS AND METHODS: A total of 9384 initial PTNBs performed in 9239 patients (mean patient age, 65 years [range, 20–99 years]) from January 2010 to December 2014 were included. The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PTNBs for diagnosis of malignancy were measured. The proportion of diagnostic failures was measured, and their risk factors were identified. RESULTS: The overall accuracy, sensitivity, specificity, PPV, and NPV were 91.1% (95% confidence interval [CI], 90.6–91.7%), 92.5% (95% CI, 91.9–93.1%), 86.5% (95% CI, 85.0–87.9%), 99.2% (95% CI, 99.0–99.4%), and 84.3% (95% CI, 82.7–85.8%), respectively. The proportion of diagnostic failures was 8.9% (831 of 9384; 95% CI, 8.3–9.4%). The independent risk factors for diagnostic failures were lesions ≤ 1 cm in size (adjusted odds ratio [AOR], 1.86; 95% CI, 1.23–2.81), lesion size 1.1–2 cm (1.75; 1.45–2.11), subsolid lesions (1.81; 1.32–2.49), use of fine needle aspiration only (2.43; 1.80–3.28), final diagnosis of benign lesions (2.18; 1.84–2.58), and final diagnosis of lymphomas (10.66; 6.21–18.30). Use of cone-beam CT (AOR, 0.31; 95% CI, 0.13–0.75) and conventional CT-guidance (0.55; 0.32–0.94) reduced diagnostic failures. CONCLUSION: The accuracy of PTNB for diagnosis of malignancy was fairly high in our large-scale multi-institutional cohort. The identified risk factors for diagnostic failure may help reduce diagnostic failure and interpret the biopsy results.
Biopsy
;
Biopsy, Fine-Needle
;
Cohort Studies
;
Cone-Beam Computed Tomography
;
Diagnosis
;
Humans
;
Image-Guided Biopsy
;
Lung Neoplasms
;
Lung
;
Lymphoma
;
Needles
;
Odds Ratio
;
Risk Factors
;
Sensitivity and Specificity
6.Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion.
Danbi LEE ; Han Chu LEE ; Jihyun AN ; Ju Hyun SHIM ; Kang Mo KIM ; Young Suk LIM ; Young Hwa CHUNG ; Yung Sang LEE
Clinical and Molecular Hepatology 2018;24(2):144-150
BACKGROUND/AIMS: Portal vein invasion (PVI) is a poor prognostic factor in patients with hepatocellular carcinoma (HCC). We intended to compare the effects of surgical resection and transarterial chemoembolization (TACE) with additional radiation therapy (RT) in HCC patients with PVI. METHODS: The subjects comprised 43 patients who underwent surgical resection for HCC with PVI without previous treatment and another 43 patients who received TACE followed by RT (TACE+RT) as initial treatment who were matched for Child-Pugh class, tumor size, and extent of PVI. Disease progression and death after the treatment were examined, and progression-free survival (PFS) and overall survival (OS) were compared between groups. Predisposing factors affecting OS were analyzed using univariate and multivariate analyses in HCC patients with PVI. RESULTS: The subjects (Age [51, 24-74; median, range], Sex [81/13; male/female], Etiology [78/1/15; hepatitis B virus {HBV}/ hepatitis C virus {HCV}/non-HBV and non-HCV]) were followed for a median of 17 (2-68) months. There were no differences in clinical or tumor characteristics between the resection and TACE+RT groups. The cumulative PFS was not significantly different between groups. The median PFS was 5.6 and 4.0 months in the resection and TACE+RT groups, respectively. However, the cumulative OS was significantly longer in patients treated with resection than in those treated with TACE+RT (P=0.04). The median OS was 26.9 and 14.2 months in the resection and TACE+RT groups, respectively. Univariate and multivariate analyses revealed that surgical resection was an independent predictive factor for better survival outcome. CONCLUSIONS: Surgical resection might be an effective treatment in HCC patients with PVI.
Carcinoma, Hepatocellular*
;
Causality
;
Disease Progression
;
Disease-Free Survival
;
Hepacivirus
;
Hepatectomy
;
Hepatitis B virus
;
Humans
;
Multivariate Analysis
;
Portal Vein*
7.Methionine Adenosyltransferase 1: A Proteomic Surrogate Marker of Early Hepatocellular Carcinoma in Cirrhotic Patients
Joo Ho LEE ; Mi Jung JUN ; Ju Hyun SHIM ; Gi Won SONG ; Eunyoung TAK ; Bora OH ; Eunsil YU ; Sang Woon CHOI ; Jihyun AN ; Danbi LEE ; Kang Mo KIM ; Young Suk LIM ; Han Chu LEE ; Young Hwa CHUNG ; Yung Sang LEE
Journal of Liver Cancer 2018;18(1):33-43
BACKGROUND/AIMS: Because there is a lack of effective biomarkers, we aimed to discover proteomic candidate markers for hepatocellular carcinoma (HCC) in cirrhotic patients at the highest-risk of HCC, and to validate the markers. METHODS: We collected tumor tissue from 5 cirrhotics with HCC, and from 5 cirrhotics without HCC, who underwent liver resection or transplantation. These tissue samples were analyzed by 2-dimensional difference gel electrophoresis coupled with matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), and potential markers were validated at the transcriptional and translational levels. We also performed western blot assays using other blood samples from 10 cirrhotics with HCC and 10 without HCC. RESULTS: Among the 66 distinguishable spots on 2-D gel images, we identified 15 proteins overexpressed more than 1.5 fold in terms of volume ratio in the tumors. Ten of the over-expressed proteins were identified by MALDI-TOF MS; of those, only methionine adenosyltransferase 1 (MAT1), a protein specific for liver, and acyl-CoA dehydrogenase were significantly up-regulated in tumors in further immunoblotting analyses (Ps<0.05). There was no between-pair difference in MAT1 mRNA measured by real-time polymerase chain reaction (P=0.96). However, in western blots of serum samples, distinct MAT1 bands were observed in all 10 HCC patients, but in only 2 of the non-HCC patients. CONCLUSIONS: MAT1 is a potential marker for surveillance in cirrhotic patients with and without prior HCC.
Acyl-CoA Dehydrogenase
;
Biomarkers
;
Blotting, Western
;
Carcinoma, Hepatocellular
;
Humans
;
Immunoblotting
;
Liver
;
Liver Cirrhosis
;
Mass Spectrometry
;
Methionine Adenosyltransferase
;
Methionine
;
Proteomics
;
Real-Time Polymerase Chain Reaction
;
RNA, Messenger
;
Two-Dimensional Difference Gel Electrophoresis
8.Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion.
Jihyun AN ; Kwang Sun LEE ; Kang Mo KIM ; Do Hyun PARK ; Sang Soo LEE ; Danbi LEE ; Ju Hyun SHIM ; Young Suk LIM ; Han Chu LEE ; Young Hwa CHUNG ; Yung Sang LEE
Clinical and Molecular Hepatology 2017;23(2):160-169
BACKGROUND/AIMS: Little is known about the treatment or outcomes of hepatocellular carcinoma (HCC) complicated with bile duct invasion. METHODS: A total of 247 consecutive HCC patients with bile duct invasion at initial diagnosis were retrospectively included. RESULTS: The majority of patients had Barcelona Clinic Liver Cancer (BCLC) stage C HCC (66.8%). Portal vein tumor thrombosis was present in 166 (67.2%) patients. Median survival was 4.1 months. Various modalities of treatment were initially employed including surgical resection (10.9%), repeated transarterial chemoembolization (TACE) (42.5%), and conservative management (42.9%). Among the patients with obstructive jaundice (n=88), successful biliary drainage was associated with better overall survival rate. Among the patients with BCLC stage C, overall survival differed depending on the initial treatment for HCC; surgical resection, TACE, systemic chemotherapy, and conservative management showed overall survival rates of 11.5, 6.0 ,2.4, and 1.6 months, respectively. After adjusting for confounders, surgical resection and repeated TACE were significant prognostic factors for HCC patients with bile duct invasion (hazard ratios 0.47 and 0.39, Ps <0.001, respectively). CONCLUSIONS: The survival of HCC patients with bile duct invasion at initial diagnosis is generally poor. However, aggressive treatments for HCC such as resection or biliary drainage may be beneficial therapeutic options for patients with preserved liver function.
Bile Ducts*
;
Bile*
;
Carcinoma, Hepatocellular*
;
Diagnosis
;
Drainage
;
Drug Therapy
;
Humans
;
Jaundice, Obstructive
;
Liver
;
Liver Neoplasms
;
Portal Vein
;
Prognosis
;
Retrospective Studies
;
Survival Rate
;
Thrombosis
9.Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate.
Yoojoo LIM ; Jee Min LIM ; Won Jae JEONG ; Kyung Hun LEE ; Bhumsuk KEAM ; Tae Yong KIM ; Tae Min KIM ; Sae Won HAN ; Do Youn OH ; Dong Wan KIM ; Tae You KIM ; Dae Seog HEO ; Yung Jue BANG ; Seock Ah IM
Cancer Research and Treatment 2017;49(4):1033-1043
PURPOSE: The purpose of this study was to assess current levels of awareness of clinical trials (CTs), perceptions regarding their benefits and willingness to participate to CTs among Korean cancer patients. MATERIALS AND METHODS: From December 2012 to August 2015, we distributed questionnaires to cancer patients receiving systemic anti-cancer therapy at Seoul National University Hospital, Seoul, Korea. RESULTS: A total of 397 out of 520 requested patients (76.3%) responded to the survey. Among the 397 patients, 62.5% were female and the median age was 52 years. Overall, 97.4% (387/397) answered that they have at least heard of CTs. When asked about their level of awareness, 23.8% (92/387) answered that they could more than roughly explain about CTs. The average visual analogue scale score of CT benefit in all patients was 6.43 (standard deviation, 2.20). Patients who were only familiar with the term without detailed knowledge of the contents had the least expectation of benefit from CTs (p=0.015). When asked about their willingness to participate in CTs, 56.7% (225/397) answered positively. Patients with higher levels of awareness of CTs showed higher willingness to participate (p < 0.001). Heavily treated patients and patients with previous experience regarding CTs also showed a higher willingness to participate (p < 0.001). The perceived benefit of CTs was higher in the group willing to participate (p=0.026). CONCLUSION: The patient’s level of awareness regarding CTs was positively related to the positive perception and willingness to participate. Although the general awareness of CTs was high, a relatively large proportion of patients did not have accurate knowledge; therefore, proper and accurate patient education is necessary.
Female
;
Humans
;
Korea
;
Patient Education as Topic
;
Seoul
;
Volition
10.Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.
Seongyeong KIM ; Ahrum MIN ; Kyung Hun LEE ; Yaewon YANG ; Tae Yong KIM ; Jee Min LIM ; So Jung PARK ; Hyun Jin NAM ; Jung Eun KIM ; Sang Hyun SONG ; Sae Won HAN ; Do Youn OH ; Jee Hyun KIM ; Tae You KIM ; David HANGAUER ; Johnson Yiu Nam LAU ; Kyongok IM ; Dong Soon LEE ; Yung Jue BANG ; Seock Ah IM
Cancer Research and Treatment 2017;49(3):643-655
PURPOSE: KX-01 is a novel dual inhibitor of Src and tubulin. Unlike previous Src inhibitors that failed to show clinical benefit during treatment of breast cancer, KX-01 can potentially overcome the therapeutic limitations of current Src inhibitors through inhibition of both Src and tubulin. The present study further evaluates the activity and mechanism of KX-01 in vitro and in vivo. MATERIALS AND METHODS: The antitumor effect of KX-01 in triple negative breast cancer (TNBC) cell lines was determined by MTT assay. Wound healing and immunofluorescence assays were performed to evaluate the action mechanisms of KX-01. Changes in the cell cycle and molecular changes induced by KX-01 were also evaluated. A MDA-MB-231 mouse xenograft model was used to demonstrate the in vivo effects. RESULTS: KX-01 effectively inhibited the growth of breast cancer cell lines. The expression of phospho-Src and proliferative-signaling molecules were down-regulated in KX-01-sensitive TNBC cell lines. In addition, migration inhibition was observed by wound healing assay. KX-01-induced G2/M cell cycle arrest and increased the aneuploid cell population in KX-01-sensitive cell lines. Multi-nucleated cells were significantly increased after KX-01 treatment. Furthermore, KX-01 effectively delayed tumor growth in a MDA-MB-231 mouse xenograft model. CONCLUSION: KX-01 effectively inhibited cell growth and migration of TNBC cells. Moreover, this study demonstrated that KX-01 showed antitumor effects through the inhibition of Src signaling and the induction of mitotic catastrophe. The antitumor effects of KX-01 were also demonstrated in vivo using a mouse xenograft model.
Aneuploidy
;
Animals
;
Breast Neoplasms
;
Cell Cycle
;
Cell Cycle Checkpoints
;
Cell Line
;
Fluorescent Antibody Technique
;
Heterografts
;
In Vitro Techniques
;
Mice
;
Microtubules
;
Mitosis*
;
src-Family Kinases*
;
Triple Negative Breast Neoplasms
;
Tubulin
;
Wound Healing

Result Analysis
Print
Save
E-mail